DiscoveRX

What DiscoveRX does

Eurofins DiscoverX (legal entity Eurofins Panlabs, Inc., previously DiscoverX Corporation) is the cell-based assay products division of Eurofins Discovery, headquartered in Fremont, California. Founded in 2000 and now operating as a subsidiary of the publicly traded Eurofins Scientific, the company develops, manufactures, and commercializes ready-to-use bioassay kits, engineered cell lines, recombinant proteins, and membrane preparations for pharmaceutical, biotechnology, and academic drug discovery customers. Its portfolio supports the full therapeutic development pipeline from target validation and high-throughput screening through lead optimization, potency testing, stability studies, and QC lot release testing.

The company's competitive foundation is its patented Enzyme Fragment Complementation (EFC) technology, a homogeneous, add-and-read detection platform that eliminates washing, centrifugation, or filtration steps and is compatible with 96- to 3456-well microplate formats. EFC underpins a family of registered assay brands including PathHunter (β-arrestin recruitment, receptor dimerization), HitHunter (kinases, GPCRs, nuclear proteins), KILR (cytotoxicity and ADCC), InCELL Hunter and InCELL Pulse (cellular target engagement, including PROTAC/degrader detection), cAMP Hunter (Gαi/o and Gs GPCR signaling), and SPRINTer (high-throughput screening). The company markets qualified bioassays optimized against marketed innovator biologics such as Tirzepatide, Semaglutide, Adalimumab, and Tocilizumab, and reports that its technology has been used in over one million programs including more than 250 stability and commercial release programs.

Commercially, DiscoverX sells primarily through a direct e-commerce platform with account-based ordering and direct sales teams across the Americas, Europe, and Asia-Pacific, supplemented by regional distributors such as Thorvacs Biotechnology in Turkey. Pricing for standardized 2-plate bioassay kits is approximately USD 1,989, with larger configurations and custom development services priced on application. Manufacturing runs from two ISO 9001:2015-certified Centers of Excellence in Fremont, California (USA) and Celle-Lévescault (France), with an additional presence in Shanghai, China. Recent product launches in May 2026 expanded the portfolio into ortholog GPCR assays for obesity and diabetes drug development, ADC screening applications, ubiquitination proteins, and emerging immuno-oncology targets.

Name

DiscoveRX

Legal name

Eurofins Panlabs, Inc.

Website

https://discoverx.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Eurofins DiscoverX is the cell-based assay products division of Eurofins Discovery, manufacturing ready-to-use bioassays, engineered cell lines, and recombinant proteins built on patented EFC technology for pharmaceutical, biotechnology, and academic drug discovery customers worldwide.

Ownership category

akta.pro rank

Product category

Drug Discovery Reagents and Cell-Based Assays

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Cell-based assays
• Drug discovery reagents
• Bioassay kits
• Recombinant proteins
• GPCR screening

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Cell-based Assay Products: Sale of ready-to-use homogeneous assay kits, stable engineered cell lines, membrane preps, recombinant proteins/enzymes, and qualified reagents for drug discovery and development. Products sold directly through e-commerce platform and sales team.
2. Bioassay Kits: Pre-configured bioassay kits for potency testing, stability studies, and lot release testing. Qualified bioassays optimized with originator drugs available at standard pricing.
3. Custom Development Services: Custom cell line development, assay development, and recombinant enzyme production capabilities for specific client requirements.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Eurofins DiscoverX develops, manufactures, and commercializes ready-to-use cell-based assays, qualified bioassay kits, engineered cell lines, membrane preparations, and recombinant proteins used by pharmaceutical and biotechnology companies for drug discovery, screening, lead optimization, and biologics characterization through commercial release. Its product portfolio is built on the proprietary Enzyme Fragment Complementation (EFC) Technology platform and spans GPCR, kinase, cytokine receptor, checkpoint receptor, ion channel, and ADCC/cytotoxicity target classes, supplied through a direct e-commerce storefront and global sales channels.

Product overview

Eurofins DiscoverX is the products division of Eurofins Discovery, offering a comprehensive portfolio of cell-based assays and reagents for drug discovery and development. The core product line is built on the proprietary Enzyme Fragment Complementation (EFC) Technology platform, which powers multiple assay brands including PathHunter® (for β-arrestin, SH2 recruitment, and dimerization detection), cAMP Hunter™ (for cAMP accumulation measurement), KILR® (for cytotoxicity/ADCC), HitHunter®, InCELL Hunter™, InCELL Pulse™, and SPRINTer™. The company offers ready-to-use bioassay kits (qualified with marketed drugs or target-based), engineered cell lines, recombinant proteins (including GPCR proteins and ubiquitination proteins), and custom development capabilities. New product launches include ortholog GPCR assays for multiple species, ADC assays, and early access programs for emerging targets. The portfolio supports the entire drug discovery pipeline from discovery through QC lot release testing, with ISO 9001:2015 certified manufacturing in the USA (San Francisco Bay Area) and France.

Differentiator

Problem solved

Functional benefit

Brands

• PathHunter: Cell-based assay platform using Enzyme Fragment Complementation technology for measuring receptor signaling, dimerization, and other biomolecular interactions
• KILR
• cAMP Hunter
• HitHunter
• InCELL
• SPRINTer
• ChemiSCREEN
• ChemiBRITE
• PrecisION
• InCELL Hunter
• InCELL Pulse

Products and services

• PathHunter Cell-based assay platform using Enzyme Fragment Complementation (EFC) technology for measuring GPCR, kinase, and other target class activities through β-arrestin recruitment, SH2 recruitment, and dimerization detection methods.
• cAMP Hunter Cell-based assay platform for measuring GPCR activity through cAMP accumulation detection using EFC technology, suitable for Gs and Gi coupled receptors.
• KILR Cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) / antibody-dependent cellular phagocytosis (ADCP) bioassay platform for measuring antibody-directed cell death using EFC technology, non-radioactive and dye-free.
• HitHunter EFC-based assay format for interrogating various biomolecular reactions in drug discovery and development programs across target classes including kinases, GPCRs, and nuclear proteins.
• InCELL Hunter Cell-based binding assays using EFC technology for detecting compound cell entry and engagement to specific intracellular and extracellular targets.
• InCELL Pulse Cellular compound target engagement assay using EFC technology to detect protein turnover induced by targeted degrader molecules such as PROTACs and to support thermal shift target engagement studies.
• SPRINTer EFC-based assay format for therapeutic drug screening and development programs, supporting high-throughput homogeneous screening formats.
• Qualified Bioassay Kits Ready-to-use, cell-based bioassay kits qualified with marketed biologic drugs or reference standards using ICH guidelines for potency testing, neutralizing antibody detection, stability studies, and lot release testing of biologic therapeutics; priced at USD 1,989 per 2-plate kit.
• Recombinant GPCR Proteins Active, purified full-length GPCR proteins supplied for ligand discovery, structural biology, and mechanism of action studies in drug discovery research.
• Ortholog GPCR Assays Cell-based assays for obesity drug development providing target coverage across human, mouse, rat, dog, and cyno/monkey species for GLP-1, GIP, and Glucagon (GCG) receptors.
• Amylin/Calcitonin Receptor Assays Mechanism-of-action reflective assays for the Amylin (AMY) and Calcitonin (CALCR) receptors intended to accelerate next-generation therapeutics for obesity and diabetes.
• ADC Assays Cell-based assays for screening and characterization of Antibody Drug Conjugates (ADCs) across their mechanism-of-action and biology.
• Ubiquitination Proteins Recombinant active, purified E1, E2, E3, and substrate proteins supplied for screening, structural analysis, and mechanism of action studies in the ubiquitination pathway.
• ChemiSCREEN Cell Lines Membrane preparation and stable cell line products for GPCR screening, supplied under a limited use label license for research and screening use.
• ChemiBRITE Cell Lines Stable GPCR reporter cell lines supplied under a limited use label license for bioluminescent reporter-based screening applications.
• PrecisION Cell Lines Human ion channel and other cell line products supplied under a royalty-free non-exclusive research-use license for research applications.
• Custom Development Capabilities Custom cell line engineering, assay development, and recombinant enzyme production services delivered for specific therapeutic program requirements from the Fremont and France Manufacturing Centers of Excellence.
• CRO Services Contract research organization services for end-to-end pharmaceutical development and small molecule drug manufacturing capabilities for early clinical trials, delivered by the broader Eurofins Discovery network.
• Early Access Program Early access program providing expedited access to innovative cell lines and ready-to-use assays, including 6-8 week lead-time bioassays for emerging targets such as Denosumab, CXCR2, CALCRL-RAMP3, MC1R, CSF1R/CSF1R, and AXL.

Quantifiable outcome

• Reduce assay development timelines by over 12 months with qualified bioassays
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

Feature8 records

Partnerships

One partnership is on record.

• Thorvacs Biotechnology LTDregionalChannel Partner/ Reseller/ DistributorInternational distributor in Turkey helping commercialize DiscoverX products into drug discovery research and screening markets. Located at Ankara Teknoloji Geliştirme Bölgesi, Bilkent Cyberpark, Ankara. Represents a committed distributor partnership model for regional market access.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Promega Corporation: Promega is a leading direct competitor in cell-based luminescence assays, best known for its NanoLuc/HiBiT reporter technology and broad portfolio of GPCR, kinase, and bioassay products — directly comparable to DiscoveRx's PathHunter and related offerings.
• Revvity (formerly PerkinElmer Life Sciences): Through the Cisbio brand, Revvity is one of DiscoveRx's closest competitors in GPCR HTRF/FRET assays and the broader cell-based assay reagents market for drug discovery screening and lot-release bioassays.
• Bio-Techne: Bio-Techne's ProteinSimple and R&D Systems brands offer recombinant proteins, cell lines, and bioassay kits overlapping with DiscoveRx's GPCR protein catalog and qualified bioassays for biologics.
• Eurofins Panlabs: Eurofins Panlabs is a sister entity offering complementary drug discovery services (safety pharmacology, ADME) and serves as the corporate/legal entity for DiscoveRx's US operations — a tightly coupled comparable rather than a true competitor.

Broad incumbents

• Merck KGaA (Sigma-Aldrich / MilliporeSigma): Merck's life science tools division (including the legacy MilliporeSigma and the Upstate kinase reagent line) competes broadly across cell-based assays, recombinant proteins, and antibody/bioassay tools — directly relevant given DiscoveRx's France site originated from this lineage.
• Thermo Fisher Scientific: Thermo Fisher offers cell-based assay reagents, instruments, and bioassay services via its Life Sciences Solutions segment, competing with DiscoveRx across reagents and providing a broad incumbent alternative for pharma procurement.
• Molecular Devices (Danaher): Molecular Devices supplies the SpectraMax/FlexStation/ImageXect readers DiscoveRx assays are validated against and provides competing cell-based assay instruments and software — a critical instrument-vendor parallel with strong customer overlap.
• Sartorius AG: Sartorius' Lab Products & Services division markets cell-based analytical instruments (e.g., Incucyte) and competing cell line/bioassay offerings, addressing similar pharma/biotech customers with broader workflow scope than DiscoveRx.

Others

• Eurofins Discovery: Eurofins Discovery is DiscoveRx's sister division offering CRO services; while it is a related entity within Eurofins Scientific, it represents a comparable distribution channel and a closely related commercial interface to the same pharma R&D customer base.

Emerging players

• AAT Bioquest: AAT Bioquest develops cell-based fluorescence and luminescence assay reagents (calcium, GPCR, cell viability), representing a smaller but directly comparable reagent-assay competitor with overlapping pharma/biotech end users.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=9NX-BcBgFAQ
• LinkedInlinkedin.com/company/eurofinsdiscoverx

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiscoveRX